Superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment during treatment of extensively drug resistant Pseudomonas aeruginosa infections in cancer patients.

Alzbeta ZavrelovaMartin SimaJana MalakovaPetra RozsivalovaPavla PaterovaPavel ZakBenjamin VisekDanica MichalickovaOndrej SlanarJakub Radocha

Published in: British journal of clinical pharmacology (2022)

We proved superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment with very low adverse effects occurrence. The off-label high-dose regimen should be used to optimize treatment of this XDR P. aeruginosa infections.

Keyphrases

high dose
drug resistant
multidrug resistant
gram negative
acinetobacter baumannii
stem cell transplantation
low dose
pseudomonas aeruginosa
cystic fibrosis
risk assessment
candida albicans